Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 6, 2013 - Issue 4
Submit an article Journal homepage
257
Views
4
CrossRef citations to date
0
Altmetric
Review

Assessing vaccine efficacy in influenza clinical trials: challenges and difficulties

Walthere Dewe GlaxoSmithKline Vaccines, Rue de l’ Institut 89, 1330 Rixensart, Belgium. [email protected]; GlaxoSmithKline Vaccines, Rue de l’ Institut 89, 1330 Rixensart, Belgium. [email protected]
,
Anne Benoit Institute of Statistics, Biostatistics and Actuarial Sciences, Université Catholique de Louvain, Voie du Roman Pays, 1348 Louvain-La-Neuve, Belgium; Institute of Statistics, Biostatistics and Actuarial Sciences, Université Catholique de Louvain, Voie du Roman Pays, 1348 Louvain-La-Neuve, Belgium
&
Catherine Legrand Institute of Statistics, Biostatistics and Actuarial Sciences, Université Catholique de Louvain, Voie du Roman Pays, 1348 Louvain-La-Neuve, Belgium; Institute of Statistics, Biostatistics and Actuarial Sciences, Université Catholique de Louvain, Voie du Roman Pays, 1348 Louvain-La-Neuve, Belgium
Pages 403-411 | Published online: 10 Jan 2014

References

  • Barr IG, McCauley J, Cox N et al.; Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2009-2010. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 28(5), 1156–1167 (2010).
  • Chan IS. Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies. Stat. Med. 17(12), 1403–1413 (1998).
  • Nauta J. Statistics in Clinical Vaccine Trials. Springer, NY, USA (2010).
  • Vesikari T, Knuf M, Wutzler P et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365(15), 1406–1416 (2011).
  • Halloran ME, Longini IM Jr, Struchiner CJ. Design and interpretation of vaccine field studies. Epidemiol. Rev. 21(1), 73–88 (1999).
  • Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338(20), 1405–1412 (1998).
  • Forrest BD, Steele AD, Hiemstra L, Rappaport R, Ambrose CS, Gruber WC. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine 29(20), 3633–3639 (2011).
  • Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355(24), 2513–2522 (2006).
  • Belshe RB, Edwards KM, Vesikari T et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356(7), 685–696 (2007).
  • Ohmit SE, Victor JC, Teich ER et al. Prevention of symptomatic seasonal influenza in 2005–2006 by inactivated and live attenuated vaccines. J. Infect. Dis. 198(3), 312–317 (2008).
  • Beran J, Wertzova V, Honegr K et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect. Dis. 9, 2 (2009).
  • Jackson LA, Gaglani MJ, Keyserling HL et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect. Dis. 10, 71 (2010).
  • Beran J, Vesikari T, Wertzova V et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J. Infect. Dis. 200(12), 1861–1869 (2009).
  • Monto AS, Ohmit SE, Petrie JG et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N. Engl. J. Med. 361(13), 1260–1267 (2009).
  • Agresti A. Categorical data analysis. Wiley, New York, USA (2002).
  • Ingram DD, Kleinman JC. Empirical comparisons of proportional hazards and logistic regression models. Stat. Med. 8(5), 525–538 (1989).
  • Agresti A. Exact inference for categorical data: recent advances and continuing controversies. Stat. Med. 20(17–18), 2709–2722 (2001).
  • Ashkenazi S, Vertruyen A, Arístegui J et al.; CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr. Infect. Dis. J. 25(10), 870–879 (2006).
  • Hoberman A, Greenberg D, Paradise J et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children – a randomized controlled trial. J. Am. Med. Assoc. 290, 1608–1616 (2003).
  • Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text. Springer, NY, USA (2012).
  • Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Springer, NY, USA (1998).
  • Senn S. Statistical Issues in Drug Development. Wiley, Chichester, UK (2007).
  • Boraschi D, Del Giudice G, Dutel C, Ivanoff B, Rappuoli R, Grubeck-Loebenstein B. Ageing and immunity: addressing immune senescence to ensure healthy ageing. Vaccine 28(21), 3627–3631 (2010).
  • John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur. J. Epidemiol. 16(7), 601–606 (2000).
  • Rappuoli R, Del Giudice G. Influenza Vaccines for the Future. Springer, NY, USA (2011).
  • Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J. Infect. Dis. 204(12), 1879–1885 (2011).
  • Haaheim LR, Katz JM. Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines. Miami, FL, USA, March 1–3, 2010. Influenza Other Respir. Viruses 5(4), 288–295 (2011).
  • Duchateau L, Janssen P. The Frailty Model. Springer, NY, USA (2008).
  • Longini IM, Halloran ME. A frailty mixture model for estimating vaccine efficacy. Appl. Statist. 45, 165–173 (1996).
  • Pickles A, Crouchley R. A comparison of frailty models for multivariate survival data. Stat. Med. 14(13), 1447–1461 (1995).
  • Berkson J, Gage RP. Survival curves for cancer patients following treatment. J. Am. Stat. Assoc. 47, 501–515 (1952).
  • McElhaney JE, Zhou X, Talbot HK et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 30(12), 2060–2067 (2012).
  • Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54(11), 1615–1617 (2012).
  • Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. Expert Rev. Vaccines 8(4), 383–389 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.